GlassScriptPhysician profile
Leo T Gozdecki
NPI 1649632118
$28,801.85
in general payments reported to CMS, 2019-2025
18 companies · $17K in 2025
The $17K reported for 2025 was more than what 83% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.30 · 2023: $9,877 · 2024: $1,477 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Grant: $9,000 · Food and Beverage: $3,205 · Travel and Lodging: $1,298 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,960.00 |
| Grant | $9,000.00 |
| Food and Beverage | $3,205.20 |
| Travel and Lodging | $1,297.79 |
| Education | $320.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $17,181.64 | 2024-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $10,427.44 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Ensite, Cardiomems |
| Cvrx, INC. | $279.33 | 2023-2025 | Barostim Neo System |
| United Therapeutics Corporation | $229.45 | 2024 | Orenitram |
| Abiomed | $197.82 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $92.35 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.06 | 2023-2024 | Lifevest |
| Paragonix Technologies, INC. | $51.85 | 2024 | Sherpapak, Pancreaspak, Baroguard |
| Novartis Pharmaceuticals Corporation | $50.03 | 2023-2025 | |
| Bridgebio Pharma, INC. | $45.33 | 2025 | Attruby |
| Daxor Corporation | $33.92 | 2025 | Bva-100 |
| Daiichi Sankyo INC. | $28.73 | 2023 | Injectafer |
| Medtronic, INC. | $27.93 | 2024 | |
| Genzyme Corporation | $25.41 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.33 | 2023 | Livtencity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $18.52 | 2023 | |
| Edwards Lifesciences Corporation | $18.30 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.41 | 2023 | Brilinta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Gozdecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.